| Disaggregation of Revenue |
The following table summarizes the disaggregation of revenue by nature: | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | Dollars in millions | 2026 | | 2025 | | 2026 | | 2025 | | Net product sales | $ | 12,588 | | | $ | 11,909 | | | $ | 23,756 | | | $ | 22,794 | | | Alliance revenues | 104 | | | 119 | | | 198 | | | 208 | | | Other revenues | 281 | | | 241 | | | 508 | | | 468 | | | Total Revenues | $ | 12,973 | | | $ | 12,269 | | | $ | 24,462 | | | $ | 23,470 | |
|
| Revenue Recognition Gross-To-Net Adjustments |
The following table summarizes GTN adjustments: | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | Dollars in millions | 2026 | | 2025 | | 2026 | | 2025 | | Gross product sales | $ | 18,179 | | | $ | 22,181 | | | $ | 35,105 | | | $ | 42,054 | | GTN adjustments(a) | | | | | | | | | Charge-backs and cash discounts | (2,372) | | | (3,407) | | | (4,839) | | | (6,365) | | | Medicaid and Medicare rebates | (1,759) | | | (4,516) | | | (3,634) | | | (8,356) | | | Other rebates, returns, discounts and adjustments | (1,460) | | | (2,348) | | | (2,876) | | | (4,538) | | Total GTN adjustments(b) | (5,592) | | | (10,272) | | | (11,349) | | | (19,260) | | | Net product sales | $ | 12,588 | | | $ | 11,909 | | | $ | 23,756 | | | $ | 22,794 | |
(a) Includes reductions/(increases) to GTN adjustments for product sales made in prior periods resulting from changes in estimates of $88 million and $67 million for the three and six months ended June 30, 2026 and $42 million and $331 million for the three and six months ended June 30, 2025, respectively. (b) Includes U.S. GTN adjustments of $4.7 billion and $9.5 billion for the three and six months ended June 30, 2026 and $9.5 billion and $17.6 billion for the three and six months ended June 30, 2025, respectively.
|
| Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue |
The following table summarizes the disaggregation of revenue by product and region: | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | Dollars in millions | 2026 | | 2025 | | 2026 | | 2025 | Growth Portfolio | | | | | | | | | Opdivo | $ | 2,485 | | | $ | 2,560 | | | $ | 4,631 | | | $ | 4,824 | | Opdivo Qvantig | 261 | | | 30 | | | 424 | | | 38 | | | Orencia | 1,034 | | | 963 | | | 1,852 | | | 1,733 | | | Yervoy | 769 | | | 728 | | | 1,420 | | | 1,351 | | | Reblozyl | 735 | | | 568 | | | 1,291 | | | 1,046 | | Breyanzi | 484 | | | 344 | | | 896 | | | 607 | | | Opdualag | 349 | | | 284 | | | 644 | | | 537 | | Camzyos | 416 | | | 260 | | | 729 | | | 419 | | | Zeposia | 169 | | | 150 | | | 287 | | | 257 | | | Sotyktu | 87 | | | 70 | | | 156 | | | 126 | | Krazati | 55 | | | 48 | | | 105 | | | 96 | | Cobenfy | 63 | | | 35 | | | 119 | | | 62 | | Other Growth products(a) | 653 | | | 557 | | | 1,234 | | | 1,063 | | Total Growth Portfolio | 7,560 | | | 6,596 | | | 13,787 | | | 12,159 | | Legacy Portfolio | | | | | | | | | Eliquis | 4,481 | | | 3,680 | | | 8,617 | | | 7,245 | | | Revlimid | 425 | | | 838 | | | 773 | | | 1,774 | | | Pomalyst/Imnovid | 204 | | | 708 | | | 717 | | | 1,366 | | | Sprycel | 88 | | | 120 | | | 160 | | | 295 | | | Abraxane | 55 | | | 105 | | | 105 | | | 210 | | Other Legacy products(b) | 170 | | | 223 | | | 326 | | | 421 | | Total Legacy Portfolio | 5,422 | | | 5,673 | | | 10,699 | | | 11,311 | | Other revenue(c) | (9) | | | — | | | (23) | | | — | | | Total Revenues | $ | 12,973 | | | $ | 12,269 | | | $ | 24,462 | | | $ | 23,470 | | | | | | | | | | | United States | $ | 8,991 | | | $ | 8,519 | | | $ | 16,779 | | | $ | 16,392 | | International | 3,664 | | | 3,481 | | | 7,108 | | | 6,590 | | Other(d) | 318 | | | 270 | | | 575 | | | 488 | | | Total Revenues | $ | 12,973 | | | $ | 12,269 | | | $ | 24,462 | | | $ | 23,470 | |
(a) Includes Abecma, Augtyro, Onureg, Inrebic, Nulojix, Empliciti and royalty revenues, including royalties received from Merck on Winrevair*. (b) Includes other mature brands. (c) Includes revenue hedging activities in 2026. (d) Other revenues include royalties and alliance-related revenues for products not sold by BMS's regional commercial organizations, including royalties received from Merck on Winrevair*.
|